Lung: Archives News of the month
Immune checkpoint inhibitors and myocarditis in advanced non-small cell lung cancer: a nationwide cohort study
Lung 5 min.
Previous evidence showed that myocarditis is a rare and life-threatening adverse event with notably increased risk among users. Myocarditis seemed to occur soon (mostly within 3 months) after initiation of immunotherapy. Return to the table of contents...
Microwave ablation of non-small cell lung cancer enhances local T-cell abundance and alters monocyte interactions
Lung 6 min.
Lung malignancy is main cause of cancer-specific mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for more than 80% of lung cancer cases [1]. Patients with early-stage NSCLC have better clinical outcomes. However, most patients are diagnosed with advanced NSCLC, and the median overall...
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study
Lung 1 min.
This study aimed to compare the efficacy and safety of rezivertinib (BPI-7711) and gefitinib as first-line therapies in patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (NSCLC). This multicentre, double-blind, randomised, phase 3 study (REZOR) included eligible patients...
Anatomic Lung Resection is Associated with Improved Survival Compared with Wedge Resection for Stage IA (≤2 cm) Non-Small Cell Lung Cancer
Lung 1 min.
Given the uncertain generalizability of recent clinical trial data, a comparative effectiveness analysis examining the long-term survival of “real world” patients may clarify the role of lobectomy and sublobar resection (segmentectomy or wedge resection) in the treatment of early-stage non-small...
Subcutaneous Versus Intravenous Pembrolizumab, in Combination With Chemotherapy, for Treatment of Metastatic Non–Small Cell Lung Cancer: The Phase 3 3475A-D77 Trial
Lung 1 min.
Pembrolizumab with berahyaluronidase alfa is for subcutaneous (SC) administration. The phase 3 open-label 3475A-D77 study (NCT05722015) assessed SC pembrolizumab versus intravenous (IV) pembrolizumab, plus chemotherapy, for treatment of metastatic non–small-cell lung cancer (mNSCLC). ...
